Clinical Trials Logo

Clinical Trial Summary

This study is aimed to determine if Metformin treatment in children born small for gestational age (SGA) who are being treated with Growth Hormone (GH) for short stature improves the response to GH by producing greater concentrations of Insulin-like growth factor -1 (IGF-1) in the blood.


Clinical Trial Description

Growth hormone treatment (GH) is recommended in children born small for gestational age (SGA) who fail to catch-up. SGA is a heterogeneous condition as reflected in the varied response to GH treatment. Variable generation and resistance to Insulin-like growth factor-1 (IGF-1), the most important circulating mediator of GH action may underpin this heterogeneity. An association between the variants in the genes related to lower insulin sensitivity and reduced IGF-1 and growth response to GH therapy in SGA children have been reported recently. The hypothesis of this study is that insulin sensitivity may be causally linked to the response to GH therapy, and adjuvant therapy with an insulin sensitizer may improve IGF-1 generation, decrease IGF-I resistance and optimise growth response.

To explore this hypothesis, this study aims to determine the effects of insulin sensitization using Metformin as an adjuvant to a fixed dose GH therapy for 6 months in short SGA children. The patients will be short SGA children between age 4 -10 years and identified from three paediatric endocrine units in Denmark, Ireland and the United Kingdom. In this mechanistic study 24 subjects starting GH treatment will be randomised in a 1:1 ratio to adjunctive Metformin or placebo for 6 months and followed-up for another 6months. The participants will receive GH treatment for the entire duration of the study (12 months) and will undergo an oral glucose tolerance test and dual-energy x-ray absorptiometry scan to determine glucose metabolism and body fat mass respectively at baseline and 6 months, and will have 3 monthly measurements of height, weight and skinfold thickness. The primary outcome will be the area under the curve of IGF-1 levels measured at 0, 1, 3 and 6 months. Secondary outcomes will include changes in insulin sensitivity, height, body fat mass and safety measures at 6 and 12 months. ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT02931591
Study type Interventional
Source Cambridge University Hospitals NHS Foundation Trust
Contact David B Dunger, MD
Phone +441223 762944
Email dbd25@cam.ac.uk
Status Not yet recruiting
Phase N/A
Start date November 2016
Completion date June 2020

See also
  Status Clinical Trial Phase
Completed NCT02218931 - ESTEEM - Effect of Simple, Targeted Diet in Pregnant Women With Metabolic Risk Factors on Pregnancy Outcomes N/A
Recruiting NCT03662178 - Investigating the Structured Use of Ultrasound Scanning for Fetal Growth
Completed NCT01697644 - Growth Hormone Treatment of Children Diagnosed of Intrauterine Growth Retardation Phase 4
Completed NCT01110928 - Observational Study of the Safety and Efficacy of Norditropin® in Patients With SGA (Small for Gestational Age) Short Stature That Are Still Growing
Completed NCT02280031 - Effect of Low Dose Aspirin on Birthweight in Twins: The GAP Trial. Phase 2
Completed NCT01245374 - Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents Phase 4
Completed NCT00184756 - Efficacy on Height in SGA Children Treated With Growth Hormone Phase 3
Completed NCT01578135 - French National Registry of Children Born Small for Gestational Age Treated With Somatropin
Recruiting NCT05603936 - Adaption and Testing of the Quality of Life in Short Stature Youth (QoLISSY) Questionnaire for Parents With Children From 0-4
Completed NCT00925925 - Epigenetic Markers of B-Cell Function in Low Birth Weight Infants N/A
Completed NCT00738205 - Evaluation of Convenience and Compliance of the Easypod™ Electronic Self-injector N/A
Completed NCT00557336 - Efficacy and Safety of Growth Hormone Treatment in Children Small for Gestational Age Phase 3
Completed NCT00371657 - Maternal Obesity and Small for Gestational Age Infants N/A
Completed NCT00519844 - Growth Hormone Treatment in Children Born Small for Gestational Age: Assessment of Satisfaction Phase 4
Completed NCT00184717 - Growth Hormone Treatment in Children Born Small for Gestational Age (SGA) Phase 3
Recruiting NCT01604395 - Long-term Safety and Effectiveness of Growth Hormone With GHD, TS, CRF, SGA , ISS and PWS in Children
Terminated NCT00597480 - Study of Growth-promoting and Metabolic Effects of Growth Hormone (rhGH) Phase 4
Completed NCT01543867 - Safety and Efficacy of Long-term Somatropin Treatment in Children N/A
Recruiting NCT02964793 - Effects of Serial Plotting on Fundal Height Charts on Identification and Outcomes of Small for Gestational Age Infants N/A
Recruiting NCT04798690 - Long-term Safety and Effectiveness of Growtropin®-II Treatment in Children With Short Stature